Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
about
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functionsDifferential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations.Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgarisDEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypesSystemic lupus erythematosus and the type I interferon systemImmunoregulatory functions of immune complexes in vaccine and therapyCross-Presentation of Cell-Associated Antigens by MHC Class I in Dendritic Cell SubsetsCross-presentation of IgG-containing immune complexesCarbohydrate-mimetic peptides for pan anti-tumor responsesMonoclonal antibodies for the treatment of cancerA crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapyRole of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunityCancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myelomaAntibodies against conserved antigens provide opportunities for reform in influenza vaccine designAntibody Therapies in Cancer.Cytokine-regulated expression and inhibitory function of FcgammaRIIB1 and -B2 receptors in human dendritic cells.Urea-mediated cross-presentation of soluble Epstein-Barr virus BZLF1 protein.Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies.Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.Recruiting dendritic cells to improve antibody therapy of cancerSelective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells.Natural immunity to pluripotency antigen OCT4 in humans.Bridging innate and adaptive antitumor immunity targeting glycans.Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants.The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunityMonoclonal antibodies: versatile platforms for cancer immunotherapy.T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Engineered antibody Fc variants with enhanced effector function.Immune complex-mediated antigen presentation induces tumor immunity.The role of dendritic cell subsets in selection between tolerance and immunity.Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas.Principles of tumor immunosurveillance and implications for immunotherapy.Targeted immunotherapy of cancer: development of antibody-induced cellular immunity.Dendritic cell-based immunotherapy for the treatment of hematological malignancies.Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice.Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virusNondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survivalSome interfaces of dendritic cell biology.
P2860
Q24532135-58704E87-B87B-4760-A7FF-E2C19E3EF9D3Q24533572-D8515CCD-2E3F-44B8-8F1F-72DE790864E0Q24676186-0896819A-49C3-44BD-AEC7-DAAE401A5F92Q24682603-C5E97659-6722-402E-A179-2B713CD3CB8CQ24804235-82055066-2B64-4819-B08B-19B1E1D7BC55Q26738396-97AA779D-3BE6-43A9-80E7-40309F8F35DDQ26799991-88FB9AB1-3D37-40ED-B288-F17E8EE654B8Q26825801-36A6A542-16AC-4CB3-A935-36F38E6BC3C2Q27023624-DC3E1CB7-2430-409D-AF7D-4314960BAFBFQ27025966-DAF14614-7A5E-4E6D-B165-95B83ABB4B04Q27314576-F1A7EF86-E2AB-4297-A475-54ED8C377C37Q28246851-EBD0A129-9E76-4055-A663-163EA46C928BQ28648164-6C97EB14-A26D-41FD-AEA9-4BA6710176DCQ30416502-928CF40A-3C52-43EA-8903-DD85F68B184FQ31104000-1DCA0963-89F1-40A1-9818-CC0B3ABDC677Q33225793-24119F29-8B11-4964-8EF6-690CE88FA47FQ33383239-5E934BF2-3017-4AA5-AAD4-C5C973DD43D6Q33576327-CE5DB7A3-2FC1-435B-8C9B-B2FC423D6F5CQ33772145-DF847F0A-D8CB-4743-8C5A-5C138ED226BEQ33772194-4F550373-DF1E-4755-BFB8-896FA33C7B67Q33865201-AF8FF33A-6D2C-4690-AA2A-E8FAC23AA3BAQ33928635-5B4D57FB-AA75-41E2-9381-80A117E7D68BQ33960021-1352D181-A2D5-4088-BEAC-012F67AE35FDQ34033969-99FBEA86-3FCA-42AE-8B0A-245AE7330CF9Q34073138-758D69A8-37CF-4D56-BDAD-3A5CDD24F9D5Q34111693-AE214DE9-1D8F-404F-B8B1-323EB3CBAD7DQ34191186-E184A16B-6350-4065-88AE-42AFFEF487F4Q34194706-D38477C0-C4D3-48F1-A434-9A427AD31929Q34424958-EE0D0AD5-B9C7-4268-B1D2-1F1717247BA3Q34793164-1CC8788A-1E36-45F5-A847-C662EE70A579Q34842295-0E5E2197-D2E4-44CE-9CF6-7EC9128A46FCQ34912810-B80BD5DA-89F5-46CC-B38B-4CFC62E6884CQ35043113-ABDBE2D7-F7A1-4334-93FC-434DC67594D3Q35084986-6E9A41D0-625A-4154-8691-CFE496C11612Q35127001-0A23FCCB-C5F8-4E62-B766-B278E7E64C79Q35157425-209FE864-D711-4796-A0C8-F64B21302332Q35173733-EC18BCBC-C686-42AE-A3B3-0A552E74FD31Q35182373-7982C849-200A-43CA-87FB-1F9AF4FD9695Q35212682-41BFF2D4-8C07-4476-AD95-335432071A31Q35219290-8DF900D4-5FBC-40EA-9F25-5F3D84F5221F
P2860
Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@ast
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@en
type
label
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@ast
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@en
prefLabel
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@ast
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@en
P2093
P2860
P356
P1476
Antitumor monoclonal antibodie ...... er T cells by dendritic cells.
@en
P2093
Barbara Williamson
Joseph Krasovsky
Kavita M Dhodapkar
Madhav V Dhodapkar
P2860
P304
P356
10.1084/JEM.20011097
P407
P577
2002-01-01T00:00:00Z